<DOC>
	<DOC>NCT01309646</DOC>
	<brief_summary>This study is designed to evaluate the safety and immunogenicity of Infanrix™-IPV+Hib vaccine when administered as a primary vaccination course to healthy Korean infants at 2, 4 and 6 months of age.</brief_summary>
	<brief_title>Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male or female between, and including, 42 and 69 days of age at the time of the first vaccination. Born after a gestation period of 37 to 42 weeks inclusive. Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) can and will comply with the requirements of the protocol. Written informed consent obtained from the parent(s)/ Legally Acceptable Representative(s) of the subject. Healthy subjects as established by medical history and clinical examination before entering into the study. Child in care. Use of any investigational or nonregistered product other than the study vaccine(s) within 30 days preceding the first dose, or planned use during the study period. Chronic administration of immunosuppressants or other immunemodifying drugs since birth. Administration of a vaccine not foreseen by the study protocol, within 30 days prior to the first study visit, with the exception of hepatitis B and Bacillus CalmetteGuérin vaccination; or planned administration during the study period, with the exception of hepatitis B and influenza vaccines, which will be allowed at least 7 days before or 30 days after the administration of the DTPa vaccine. Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a noninvestigational product. Evidence of previous or intercurrent diphtheria, tetanus, pertussis, poliomyelitis and Hib vaccination or disease. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. Family history of congenital or hereditary immunodeficiency. History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s). Major congenital defects or serious chronic illness. History of any neurological disorders or seizures. Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period. Acute disease and/or fever at the time of enrolment.</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>69 Days</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Primary vaccination</keyword>
	<keyword>combination vaccine</keyword>
	<keyword>South Korea</keyword>
</DOC>